Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Zhongyuan Union Cell & Gene Engineering's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 23.23%.
SHSE:600645'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10.98 Med: 17.49 Max: 30.68
Current: 30.68
During the past 13 years, Zhongyuan Union Cell & Gene Engineering's highest ROC (Joel Greenblatt) % was 30.68%. The lowest was -10.98%. And the median was 17.49%.
SHSE:600645's ROC (Joel Greenblatt) % is ranked better than 89.39% of 1320
companies
in the Biotechnology industry
Industry Median: -300.315
vs SHSE:600645: 30.68
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600645 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongyuan Union Cell & Gene Engineering ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 23.23% mean?
Zhongyuan Union Cell & Gene Engineering (SHSE:600645) has a ROC (Joel Greenblatt) % of 23.23% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. This is 33% above median its historical median of 17.49. According to the industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #140 out of 1320 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Zhongyuan Union Cell & Gene Engineering's ROC (Joel Greenblatt) % too high?
Zhongyuan Union Cell & Gene Engineering's current ROC (Joel Greenblatt) % of 23.23% is 33% above median its 10-year median of 17.49. Based on the distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #140 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zhongyuan Union Cell & Gene Engineering has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhongyuan Union Cell & Gene Engineering's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhongyuan Union Cell & Gene Engineering ranks #140 out of 1320 companies for ROC (Joel Greenblatt) %. This places Zhongyuan Union Cell & Gene Engineering in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Zhongyuan Union Cell & Gene Engineering and its competitors. Zhongyuan Union Cell & Gene Engineering's current ROC (Joel Greenblatt) % is 23.23%, which is 33% above median its own 10-year median of 17.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongyuan Union Cell & Gene Engineering stock overvalued right now?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering (SHSE:600645) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.47, compared to a current price of ¥19.95 — trading 8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 23.23%, which is 33% above median its 10-year median of 17.49. Zhongyuan Union Cell & Gene Engineering's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Zhongyuan Union Cell & Gene Engineering (SHSE:600645), the current ROC (Joel Greenblatt) % is 23.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongyuan Union Cell & Gene Engineering stock appears to be overvalued.
The current stock price of ¥19.95 is trading 8% above its estimated GF Value™ of ¥18.47.
GuruFocus considers Zhongyuan Union Cell & Gene Engineering to be Fairly Valued.
Key valuation signals for SHSE:600645:
ROC (Joel Greenblatt) %: 23.23% (33% above median its 10-year median of 17.49)
GF Value™: ¥18.47 vs. price of ¥19.95 (8% above fair value)
No single metric tells the full story. See the SHSE:600645 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
65GF Score
Get the complete analysis for SHSE:600645
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600645 has been successfully added to your 
